Standard Chem & Pharm CO., LTD.

Taiwan Stock Exchange 1720.TW

Standard Chem & Pharm CO., LTD. Price to Earnings Ratio (P/E) on January 14, 2025: 12.18

Standard Chem & Pharm CO., LTD. Price to Earnings Ratio (P/E) is 12.18 on January 14, 2025, a -11.20% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Standard Chem & Pharm CO., LTD. 52-week high Price to Earnings Ratio (P/E) is 402.77 on December 20, 2024, which is 3,207.08% above the current Price to Earnings Ratio (P/E).
Standard Chem & Pharm CO., LTD. 52-week low Price to Earnings Ratio (P/E) is 12.05 on January 13, 2025, which is -1.09% below the current Price to Earnings Ratio (P/E).
Standard Chem & Pharm CO., LTD. average Price to Earnings Ratio (P/E) for the last 52 weeks is 15.15.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Taiwan Stock Exchange: 1720.TW

Standard Chem & Pharm CO., LTD.

CEO	Mr. Tzu-Ting Fan
IPO Date	Jan. 4, 2000
Location	Taiwan
Headquarters	No. 6-20, Tuku
Employees	1,130
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Standard Chem & Pharm CO., LTD. engages in the manufacture and sale of pharmaceutical products, supplements, and APIs in Taiwan. It offers various pharmaceutical products, including circulatory system, digestive system, respiratory system, antihistamine, C.N.S, metabolism, anti-microbial, and skin and mucous membrane drugs, as well as human and veterinary APIs, and excipients. The company was founded in 1967 and is headquartered in Tainan City, Taiwan.

Key trends

Past 5 years